WWW Weill Cornell Medical College, 9-3-2015---(Richard R. Furman, M.D. Medical Oncology)

A phase 1 study of the selective PI3δ inhibitor idelalisib (GS-1101) in combination with therapeutic anti-CD20 antibodies (rituximab or ofatumumab) in patients with relapsed or refractory chronic lymphocytic leukemia, 2013---p. 2 (Richard R. Furman, MD. Weill Cornell Medical College, New York)